Compound 126 alone or in combination with sorafenib can inhibit hepatocellular carcinoma (HCC) proliferation, induce apoptosis and cell cycle arrest, displace BRD4 from the MYC transcriptional start point, and inhibit HCC growth in vivo by interfering with the PI3K/AKT/mTOR, and Ras/Raf/MAPK singling pathways. The gene discussed is MTOR; the disease is hepatocellular carcinoma.